|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC17 |
Gene summary for TTC17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC17 | Gene ID | 55761 |
| Gene name | tetratricopeptide repeat domain 17 | |
| Gene Alias | TTC17 | |
| Cytomap | 11p12-p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q6MZP1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55761 | TTC17 | CCI_2 | Human | Cervix | CC | 2.09e-03 | 7.80e-01 | 0.5249 |
| 55761 | TTC17 | CCI_3 | Human | Cervix | CC | 3.39e-09 | 7.30e-01 | 0.516 |
| 55761 | TTC17 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.48e-32 | -7.73e-01 | 0.0155 |
| 55761 | TTC17 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.30e-10 | -6.91e-01 | -0.1808 |
| 55761 | TTC17 | HTA11_2951_2000001011 | Human | Colorectum | AD | 7.49e-08 | -9.50e-01 | 0.0216 |
| 55761 | TTC17 | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.04e-04 | -6.76e-01 | -0.2196 |
| 55761 | TTC17 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.37e-16 | -8.97e-01 | -0.1207 |
| 55761 | TTC17 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.15e-03 | -5.43e-01 | -0.1526 |
| 55761 | TTC17 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.94e-16 | -5.54e-01 | -0.1464 |
| 55761 | TTC17 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.97e-03 | -3.42e-01 | -0.1001 |
| 55761 | TTC17 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.98e-09 | -8.08e-01 | -0.2061 |
| 55761 | TTC17 | HTA11_5216_2000001011 | Human | Colorectum | SER | 5.95e-05 | -7.95e-01 | -0.1462 |
| 55761 | TTC17 | HTA11_9341_2000001011 | Human | Colorectum | SER | 4.74e-04 | -7.16e-01 | -0.00410000000000005 |
| 55761 | TTC17 | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.64e-04 | -4.91e-01 | -0.0179 |
| 55761 | TTC17 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.11e-19 | -7.49e-01 | 0.096 |
| 55761 | TTC17 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.33e-03 | -8.81e-01 | 0.0451 |
| 55761 | TTC17 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.91e-12 | -8.83e-01 | 0.0528 |
| 55761 | TTC17 | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.39e-02 | -5.94e-01 | 0.0171 |
| 55761 | TTC17 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.43e-10 | -5.93e-01 | 0.0338 |
| 55761 | TTC17 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.73e-10 | -4.78e-01 | 0.0674 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
| GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
| GO:00300419 | Cervix | CC | actin filament polymerization | 45/2311 | 191/18723 | 1.20e-05 | 2.54e-04 | 45 |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
| GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
| GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
| GO:00070151 | Colorectum | SER | actin filament organization | 134/2897 | 442/18723 | 1.39e-15 | 5.70e-13 | 134 |
| GO:00081541 | Colorectum | SER | actin polymerization or depolymerization | 77/2897 | 218/18723 | 3.50e-13 | 1.19e-10 | 77 |
| GO:00300411 | Colorectum | SER | actin filament polymerization | 70/2897 | 191/18723 | 5.39e-13 | 1.65e-10 | 70 |
| GO:00512581 | Colorectum | SER | protein polymerization | 91/2897 | 297/18723 | 2.72e-11 | 5.06e-09 | 91 |
| GO:00070152 | Colorectum | MSS | actin filament organization | 146/3467 | 442/18723 | 1.16e-13 | 2.67e-11 | 146 |
| GO:00081542 | Colorectum | MSS | actin polymerization or depolymerization | 79/3467 | 218/18723 | 4.14e-10 | 3.49e-08 | 79 |
| GO:00300412 | Colorectum | MSS | actin filament polymerization | 71/3467 | 191/18723 | 8.77e-10 | 6.92e-08 | 71 |
| GO:00512582 | Colorectum | MSS | protein polymerization | 97/3467 | 297/18723 | 2.98e-09 | 2.07e-07 | 97 |
| GO:00070154 | Colorectum | FAP | actin filament organization | 125/2622 | 442/18723 | 1.97e-15 | 3.03e-12 | 125 |
| GO:00081544 | Colorectum | FAP | actin polymerization or depolymerization | 60/2622 | 218/18723 | 1.15e-07 | 7.43e-06 | 60 |
| GO:00300414 | Colorectum | FAP | actin filament polymerization | 53/2622 | 191/18723 | 4.65e-07 | 2.46e-05 | 53 |
| GO:00512584 | Colorectum | FAP | protein polymerization | 73/2622 | 297/18723 | 7.11e-07 | 3.32e-05 | 73 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC17 | SNV | Missense_Mutation | novel | c.2908G>T | p.Ala970Ser | p.A970S | Q96AE7 | protein_coding | tolerated(0.38) | possibly_damaging(0.551) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| TTC17 | SNV | Missense_Mutation | novel | c.3082A>G | p.Lys1028Glu | p.K1028E | Q96AE7 | protein_coding | tolerated(0.18) | probably_damaging(0.98) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| TTC17 | SNV | Missense_Mutation | c.2881G>T | p.Asp961Tyr | p.D961Y | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TTC17 | SNV | Missense_Mutation | c.412N>T | p.Asp138Tyr | p.D138Y | Q96AE7 | protein_coding | deleterious(0.02) | possibly_damaging(0.736) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTC17 | SNV | Missense_Mutation | novel | c.3080N>G | p.Val1027Gly | p.V1027G | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
| TTC17 | SNV | Missense_Mutation | c.1552G>A | p.Glu518Lys | p.E518K | Q96AE7 | protein_coding | tolerated(0.58) | benign(0.106) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TTC17 | SNV | Missense_Mutation | c.334N>T | p.Pro112Ser | p.P112S | Q96AE7 | protein_coding | tolerated(0.28) | benign(0.34) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTC17 | SNV | Missense_Mutation | c.751N>G | p.Arg251Gly | p.R251G | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| TTC17 | SNV | Missense_Mutation | rs765970018 | c.1429N>A | p.Val477Ile | p.V477I | Q96AE7 | protein_coding | tolerated(0.39) | benign(0.06) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| TTC17 | insertion | Frame_Shift_Ins | novel | c.2137_2138insTATTATATATTAGTCTTTT | p.Arg713IlefsTer20 | p.R713Ifs*20 | Q96AE7 | protein_coding | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |